Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
We developed an human cardiac alpha-myosin -induced myocarditis model in human HLA-DR4 transgenic mice that lack all mouse MHCII genes.
Strong association of nontumor anti-LGI1 encephalitis with HLA-DRB4.
HLA-DR4 is a susceptibility factor for the development of AIH. Impaired suppressive function of Tregs and reduced PD-1 expression may result in spontaneous activation of key immune cell subsets, such as antigen-presenting cells and CD8(+) T effectors, facilitating the induction of AIH and persistent liver damage.
HLA-DRB4 affects type 1 diabetes risk and islet autoantibodies.
The study identifies a region of focus for B and T cell responses to IA-2 in HLA-DR4 diabetic patients that may explain HLA associations of IA-2 autoantibodies.
HLA-DR4 codes for susceptibility to RF+ polyarticular JIA with a six-fold risk.
The HLA- DR4 gene was clearly associated with susceptibility to rheumatoid arthritis.
There was a strong association of aspirin resistant thrombophilia with expression of HLA-DRB4 and HLA-DQA1.
Heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia.
Data indicate that invariant NKT (iNKT) cell-mediated cytokine secretion in staphylococcal enterotoxin B (SEB)-challenged HLA-DR4-transgenic mice was CD1d-independent.
There are no significant differences in the HLA-DRB3/B4/B5 homozygosity and heterozygosity rates between Korean males and females in both newborns and adults.
Elevated frequencies of HLA-DR4 and HLA-DR5 alleles were found in patients with idiopathic dilated cardiomyopathy compared with controls.
DRB4*01:08 is a novel HLA-DRB4 allele
HLA-DR14/DR7/DQ5 alleles significantly increase the risk for toxic shock syndrome, regardless of individual variations in T cell receptor variable region repertoires.
IA2 positivity was associated with HLA-DR4/X and HLA-DR3/4 positivity, and hypothyroidism was linked to HLA-DR4/4. More females carried the HLA-DR4/4 genotype or were thyroid antibody positive.
Our results revealed HLA-DRB1*04 as predisposing factor in papillary thyroid carcinoma in Iranian population.
Complete coding sequence of the HLA alleles DRB4*0103101 and DRB4*01033
DRB4 was increased in males with childhood ALL compared to age- and sex-matched controls) and female patients. HLA-DRB4 is over-represented in high-risk patients. The HLA system may be a component of genetic leukemia susceptibility in male children only.
Comparison of HLA-DR4-associated peptides in neuroendocrine cells with those identified in lymphoblastoid B cells (LCLs) suggests that intracellular pathways allowing HLA-DR endogenous peptide processing are more efficient in endocrine cells than in LCLs.
A novel allele of HLA-DRB4 was found.
HLA-DRB4 belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DRA) and a beta (DRB) chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. DRB1 is expressed at a level five times higher than its paralogues DRB3, DRB4 and DRB5. The presence of DRB4 is linked with allelic variants of DRB1, otherwise it is omitted. There are 4 related pseudogenes: DRB2, DRB6, DRB7, DRB8 and DRB9.
DRB1 transplantation antigen
, HLA class II histocompatibility antigen, DR beta 4 chain
, MHC HLA DR-beta chain
, MHC class II antigen DRB4
, MHC class II antigen HLA-DR-beta
, MHC class2 antigen
, human leucocyte antigen DRB4
, leukocyte antigen